Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.. we may have a therapeutic resolve-ment very quickly very very quickly that's the one I'd rather have faster because you go in give a transfusion or a shot to people that are very ill and they could come out of the hospital the next day or a few days later ..
..sounds like Relief Therapeutics results.. and he said very quickly..
.. ;) New boards were just opened hitting top read lists there also..
US passes 5 Million; Coronavirus live news: UK daily infections pass 1,000 as Greece posts highest single rise
https://www.theguardian.com/world/live/2020/aug/09/coronavirus-live-news-us-nears-5m-cases-as-australian-border-closures-ramp-up?CMP=share_btn_tw
$RLFTF RLF-100. Details.
In late March
Preparing for a phase II trial of intravenous Aviptadil for COVID-19-associated acute respiratory distress; filed an IND with the FDA.
April 9, it entered FDA clinical trials at Thomas Jefferson University Hospital in Philadelphia to treat acute respiratory distress syndrome in COVID-19; the trial will enroll patients who are already on mechanical ventilation;
May 11, Neurorx filed investigational protocol with FDA under the Coronavirus Treatment Acceleration Program for a phase II/III study assessing inhaled drug in patients with non-acute lung injury due to COVID-19;
May 14, final manufacturing completed for phase IIb/III trial to assess intravenous formulation in individuals on mechanical ventilation; enrollment initiated at first U.S. site;
June 2, treated first of 120 patients in phase IIb/III study; primary endpoints are mortality and index of respiratory distress;
June 8, expanded a phase II study to include patients receiving high flow oxygen and noninvasive ventilation, in addition to those on ventilators;
June 11, added Houston Methodist Hospital as a research site;
June 24, FDA granted fast track designation for treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19;
July 16, data monitoring committee reviewed findings from the first 30 patients, concluding that the study should continue;
July 29, FDA granted expanded access protocol to those ineligible for enrollment in clinical trial, including pregnant women, who exhausted approved therapies;
Aug. 3, Neurorx and Relief said RLF-100 allowed rapid recovery from respiratory failure in the most critically ill COVID-19 patients; independent researchers reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes; RLF-100 was granted fast track designation by the FDA and is being developed as a material threat medical countermeasure with the U.S. NIH and other federal agencies; RLF-100 is a patented formulation of vasoactive intestinal polypeptide;
Aug. 6, FDA approved the IND for the phase II/III study
Details From Bioworld.com. (Therapeutics In Development)
$RLFTF RLF-100. Details.
In late March
Preparing for a phase II trial of intravenous Aviptadil for COVID-19-associated acute respiratory distress; filed an IND with the FDA.
April 9, it entered FDA clinical trials at Thomas Jefferson University Hospital in Philadelphia to treat acute respiratory distress syndrome in COVID-19; the trial will enroll patients who are already on mechanical ventilation;
May 11, Neurorx filed investigational protocol with FDA under the Coronavirus Treatment Acceleration Program for a phase II/III study assessing inhaled drug in patients with non-acute lung injury due to COVID-19;
May 14, final manufacturing completed for phase IIb/III trial to assess intravenous formulation in individuals on mechanical ventilation; enrollment initiated at first U.S. site;
June 2, treated first of 120 patients in phase IIb/III study; primary endpoints are mortality and index of respiratory distress;
June 8, expanded a phase II study to include patients receiving high flow oxygen and noninvasive ventilation, in addition to those on ventilators;
June 11, added Houston Methodist Hospital as a research site;
June 24, FDA granted fast track designation for treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19;
July 16, data monitoring committee reviewed findings from the first 30 patients, concluding that the study should continue;
July 29, FDA granted expanded access protocol to those ineligible for enrollment in clinical trial, including pregnant women, who exhausted approved therapies;
Aug. 3, Neurorx and Relief said RLF-100 allowed rapid recovery from respiratory failure in the most critically ill COVID-19 patients; independent researchers reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes; RLF-100 was granted fast track designation by the FDA and is being developed as a material threat medical countermeasure with the U.S. NIH and other federal agencies; RLF-100 is a patented formulation of vasoactive intestinal polypeptide;
Aug. 6, FDA approved the IND for the phase II/III study
Details From Bioworld.com. (Therapeutics In Development)
Thanks, I grabbed a starter,,,
Thanks for the replies all.. ..from the looks of the passion in this guy to save his wife others may go for the desperate measures and get the job done. FDA or no ;)
Brutal in BRAZIL
..will other Countries use this for Covid-19 even before any FDA nod?
$RLFTF Here it is. It stops replication of the virus and blocks cytokine storm, imo.
Quote:
aviptadil is shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes while also preventing synthesis of cytokines in the lung. It is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA fast track designation, FDA emergency use IND authorisation, and an expanded access protocol.
https://www.thechronicleherald.ca/news/world/fda-lets-neurorx-relief-therapeutics-test-rlf-100-in-covid-19-patients-481945/
$RLFTF
"Dramatic Recovery Results"
WORLD WIDE COVERAGE https://health.economictimes.indiatimes.com/news/pharma/new-drug-rlf-100-shows-dramatic-recovery-in-covid-19-patients-suffering-respiratory-failure/77390990
DRAMATIC RECOVERY RESULTS !!
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis.
//
Relief Therapeutics also holds a U.S. patent (US8178489 formulation for aviptadil) for RLF-100 and proprietary manufacturing processes for its synthesis.
//
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF.
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.
..that and people are wary of long term vaccine side effects to begin with..
$RLFTF Some notes from another place
One thing we all need to remember. This product is already approved for a different medical application. So it’s cleared all the FDA test in the body. Now just checking if it can be used in the lungs specifically. That moves us way ahead in the timeline.
Reply
Our body makes it naturally, this is just a synthetic form.
Bullish
Reply
It’s been used for pulmonary fibrosis for many years
Reply
Great point
$RLFTF #1 Most Read Boards Relief Therapeutics Last Hour 2,351 Reads
49,497 Last 24 Hours
... Sippin' on gin and juice, laid back. With my mind on my money. And my money on my mind
$HTDS I was able to put a GTC sell order in.. mmh ?? wasn't able to put in anything for the longest time..
$RLFTF. That's Heavy.
Life Saving RLF-100
https://arizonadailyindependent.com/valley-husband-fighting-for-wifes-right-to-try-to-defeat-covid-19/
Revive helps protect the heart/lungs ?
Health experts worry coronavirus could cause lasting heart complications for athletes http://a.msn.com/02/en-us/BB17IQqk?ocid=st
..just look at his posting history.. ;)
Therapeutics will take center stage: IMO - Dr. Anthony Fauci says chance of coronavirus vaccine being highly effective is 'not great'
https://cnb.cx/3ikdN0O
Therapeutics will take center stage: IMO - Dr. Anthony Fauci says chance of coronavirus vaccine being highly effective is 'not great'
https://cnb.cx/3ikdN0O
Answer: no direct user fees, but there are fees taken off of the total fund.
RELIEF !! Trumps gonna like saying that.. Relief !! that and Revive.. ;)
I like both of 'em !!
2b/ hundreds of millions will be locked up in long term dollar land hands
Hey Dude OT - Q .. I was wondering if those ETF's have fees or does it trade like any other stock ? NRGU is the one I'm looking at and I see you had Velocityshares 3X Long Natural Gas Etn ... Thanks
Good point made on another board: The thing about (edit:other ther's) is they are testing in mild to moderate patients. This would be used a lot more than people on their death bed. This may actually keep people from getting to the death bed. - septmike09
....there is enough room for all the players on the front line IMO
GOOD POINT !! will be more widely used.. ;) - clemdane (reply below)
IPIX Innovation Pharmaceuticals Inc.
Canada Approves the Use of Psilocybin Mushrooms for Terminally Ill Patients
https://www.thecannabisinvestor.ca/canada-approves-the-use-of-psilocybin-mushrooms-for-terminally-ill-patients/?mc_cid=ee262d5a1d&mc_eid=936752ddb1
I have both... not selling any Revive at this point from what I am hearing there will be many approaches in therapeutics and relief and revive are alike but this one also deals with inflammation and protects the heart.. so I don't think RVVTF is going off a cliff.. I actually put an order in for some IPeyeX there will be many approaches CO (collective opinion)
mmh, lots of members here.. can't take a second to answer.. God bless 'em
..maybe I'll write the fund.
..these points would be scary except for one hold up.. why would Lebby throw his rep away for this? He's already wealthy and did vet this while on the board.. so I can't put him in the same category with the previous management. IMO
aww man ..
We will do well !! MONSTER $$ on the way:)
$RLFTF WOW - NEWS - FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
https://marketwirenews.com/news-releases/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to--5364790024303465.html?i=t&utm_source=dlvr.it&utm_medium=twitter
$RLFTF WOW - NEWS - FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
https://marketwirenews.com/news-releases/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to--5364790024303465.html?i=t&utm_source=dlvr.it&utm_medium=twitter
$RLFTF WOW - NEWS - FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
https://marketwirenews.com/news-releases/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to--5364790024303465.html?i=t&utm_source=dlvr.it&utm_medium=twitter
..don't be that phone guy and bad mouth another company that you were just with.. can you hear me now.
$RLFTF Looking Good